Severe leucopenia associated with Sitagliptin use

Diabetes Research and Clinical Practice

Volumn 91, Issue 2, 2011, Pages

  Pitocco, Dario ^a   Zaccardi, Francesco ^a   Martini, Francesca ^a   Scavone, Giuseppe ^a   Musella, Tittania ^a   Caputo, Salvatore ^a   Ghirlanda, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Dipeptidil peptidase 4 enzyme; Immunological effects; Sitagliptin; Type 2 diabetes

Indexed keywords

ATORVASTATIN; HEMOGLOBIN; HEMOGLOBIN A1C; IRBESARTAN; METFORMIN; REPAGLINIDE; SITAGLIPTIN;

AGED; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CLINICAL EXAMINATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG WITHDRAWAL; GRANULOCYTOPENIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEUKOPENIA; LYMPHOCYTOSIS; MALE; MEDICAL HISTORY; MONOCYTOSIS; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMOCHROMIC NORMOCYTIC ANEMIA; THYROIDECTOMY;

AGED; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LEUKOPENIA; MALE; PYRAZINES; TRIAZOLES;

EID: 79952041480     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.10.004     Document Type: Article

References (13)

1. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298(2 (July 11)):194-206. Review.
2. ; last visit November 10; 2009. http://www.emea.europa.eu/humandocs/Humans/EPAR/januvia/januvia.htm2.
3. Ohnuma K., Dang N.H., Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008, 29(6):295-301. Review.
4. DeMeester I., KoromS, Van Damme J., Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999, 20:367-375.
5. Kirby M., Yu D.M., O'Connor S., Gorrell M.D. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2009, 118(1 (September 28)):31-41. Review.
6. Broxmeyer H.E. Chemokines in hematopoiesis. Curr Opin Hematol 2008, 15(1 (January)):49-58. Review.
7. Lankas G.R., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54(10 (October)):2988-2994.
8. Klemann C., et al. CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently. Clin Exp Immunol 2009, 155(2 (February)):357-365.
9. Yan S., Marguet D., Dobers J., Reutter W., Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003, 33:1519-1527.
10. Moore M.A. Cytokine and chemokine networks influencing stem cell proliferation, differentiation, and marrow homing. J Cell Biochem Suppl 2002, 38:29-38.
11. Stulc T., Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?. Diabetes Res Clin Pract 2010, 88(2 (May)):125-131.
12. Weihofen W.A., Liu J., Reutter W., Saenger W., Fan H. Crystal structures of HIV-1 Tat-derived nonapeptides Tat-(1-9) and Trp2-Tat-(1-9) bound to the active site of dipeptidyl-peptidase IV (CD26). J Biol Chem 2005, 280(15 (April 15)):14911-14917.
13. Kramer M.S., Leventhal J.M., Hutchinson T.A., Feinstein A.R. An algorithm for the operational assessment of adverse drug reactions: I. Background, description, and instructions for use. JAMA 1979, 242:623-632.